Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Participants have voluntarily agreed to participate by giving written informed consent.~2. Age 18 years (including 18 years) on the day of signing informed consent.~3. Participants meet the following eligibility criteria for the corresponding part of the study: 1) In Phase 1 portion: The participants must have a histologically or cytologically confirmed locally advanced or metastatic cancer, either triple-negative breast cancer or epithelial, non-mucinous, high-grade ovarian cancer (including fallopian cancer, or primary peritoneal cancer), for which no effective standard therapy is available.~2) In Phase 2 portion: Participants who have histologically or cytologically confirmed high-grade epithelial ovarian cancer (including fallopian cancer or primary peritoneal cancer), harboring germline BRCA1/2 mutation 4. Participants must have measurable disease as defined per the RECIST, version 1.1.~5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1~Key Exclusion Criteria:~1. Participants who have been treated with chemotherapy, biologic therapy, immunotherapy, investigational agent, anti-cancer Chinese medicine, or anticancer herbal remedies ≤ 14 days (or ≤5 half-lives, whichever is shorter) prior to starting study drug, or who have not adequately recovered from the side effects of such therapy.~2. Participants who have undergone major surgery for any cause ≤ 4 weeks prior to starting study drug. Participants must have adequately recovered from the previous treatment and have a stable clinical condition before entering the study.~3. Participants who have undergone radiotherapy for any cause ≤ 14 days prior to starting study drug. Participants must have adequately recovered from the previous treatment and have a stable clinical condition before entering the study.~4. Untreated and/or active brain metastases.~5. Prior therapies targeting poly (ADP-ribose) polymerase (PARP).~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: 20 milligram (mg) pamiparib (Type: EXPERIMENTAL): 20 mg pamiparib twice a day for 21 days
- Phase 1 : 40 mg pamiparib (Type: EXPERIMENTAL): 40 mg pamiparib twice a day for 21 days
- 60 mg pamiparib (Type: EXPERIMENTAL): 60 mg pamiparib twice a day for 21 days
- 60 mg pamiparib in platinum-sensitive ovarian cancer (PSOC) (Type: EXPERIMENTAL): 60 mg pamiparib twice a day until occurrence of unacceptable toxicities, disease progression, withdrawal of consent or investigator discretion
- 60 mg pamiparib in platinum resistant ovarian cancer (PROC) (Type: EXPERIMENTAL): 60 mg pamiparib twice a day until occurrence of unacceptable toxicities, disease progression, withdrawal of consent or investigator discretion

Based on this trial design, predict the completion outcome and termination type (if applicable).